Dr Rifca Le Dieu

Dr Rifca Le Dieu

MB BS, FRCP, PhD
Centre: Haemato-Oncology
Clinical Senior Lecturer
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


I am interested in understanding how cancer cells ‘switch off’ the normal immune response in acute myeloid leukaemia with the aim of developing novel immunotherapeutic strategies.

Research Details

I am currently developing several research projects:

  1. MicroRNA mediated anti-tumour T cell responses in acute myeloid leukaemia
  2. The role of T cells in the evolution of acute myeloid leukaemia from myelodysplasia

Profile

I started work in the Haemato-Oncology department in the Barts Cancer Institute in October 2011 as part of John Gribben’s cancer immunotherapy group. I developed my research interests as an MRC Clinical Training Fellow in the group between 2005 and 2009 when I investigated T cells in acute myeloid leukaemia. I gained experience in immunomagnetic cell separation, flow cytometry, gene expression profiling and confocal microscopy of the immune synapse.

I developed a technique for separating T cells from the peripheral blood of patients presenting with AML that was published in the Journal of Immunological Methods in 2009 and my data characterising T cell defects in AML was published in Blood in the same year. I left Barts in 2009 to complete my clinical haematology training which included a year spent at the Hammersmith Hospital as a stem cell transplant coordinator. During this time, I gained valuable experience in the organisation as well as inpatient and outpatient management of patients undergoing allogeneic stem cell transplantation.

I now plan to develop as an independent researcher taking forward my basic science research examining T cell function in haematologic malignancy to investigate new immunotherapeutic strategies in AML.

Funding

  • 2012: Barts and the London Charity Clinical Research Training Fellowship - "Improving allogeneic T cell responses to tumour using lenalidomide" £125,093
  • British Society of Haematology

Key Publications

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Le Dieu R, Taussig D, Ramsay AG, Mitter R, Lee AM, Lister TA, Gribben JG. Blood 2009 Oct; 114 (18): 3909-16 PMID: 19710498

Array-based DNA methylation profiling in follicular lymphoma. O’Riain C, O’Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosen L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, John son N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J. Leukemia 2009 Oct; 23 (10): 1858-66 PMID: 19587707

Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. Le Dieu R, Taussig D, Lister TA, Gribben JG. Journal of Immunological Methods 2009 Aug ; 348 (1-2): 95-100 PMID: 19576900

Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T cell dysfunction. Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce C, Gribben JG. PNAS 2009 Apr; 106 (15): 6250-6255 PMID: 19332800


Further Publications

For additional publications, please click here


I am interested in understanding how cancer cells ‘switch off’ the normal immune response in acute myeloid leukaemia with the aim of developing novel immunotherapeutic strategies.

See other researchers working on:

Blood cancers Clinical Trials Immunology Leukaemia
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.